The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus
Authors
Keywords
-
Journal
RESPIRATORY MEDICINE
Volume -, Issue -, Pages 107455
Publisher
Elsevier BV
Online
2023-11-03
DOI
10.1016/j.rmed.2023.107455
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of inhaled antibiotics in the era of highly effective CFTR modulators
- (2023) J. Stuart Elborn et al. European Respiratory Review
- The lung microbiota in children with cystic fibrosis captured by induced sputum sampling
- (2022) Rebecca Weiser et al. Journal of Cystic Fibrosis
- Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis
- (2022) Clémence Martin et al. Journal of Cystic Fibrosis
- Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles
- (2022) Simon Y. Graeber et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
- (2022) Caitlyn Harvey et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
- (2022) Kevin W. Southern et al. Journal of Cystic Fibrosis
- The Changing Epidemiology of Cystic Fibrosis
- (2022) Pierre-Régis Burgel et al. CHEST
- Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
- (2022) Nicole Mayer-Hamblett et al. Lancet Respiratory Medicine
- Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
- (2021) Pierre-Régis Burgel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 Through 11 Years of Age With CF and at Least One F508del Allele
- (2021) Edith T. Zemanick et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A new era for people with cystic fibrosis
- (2021) Marlou C. Bierlaagh et al. EUROPEAN JOURNAL OF PEDIATRICS
- Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
- (2021) Sivagurunathan Sutharsan et al. Lancet Respiratory Medicine
- Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥24 Weeks in People With CF and ≥1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial
- (2020) Matthias Griese et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
- (2020) Andrea Gramegna et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials
- (2019) Gwyneth Davies et al. Journal of Cystic Fibrosis
- Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy
- (2019) Alex H. Gifford et al. Journal of Cystic Fibrosis
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
- (2019) Harry G M Heijerman et al. LANCET
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
- (2019) Peter G. Middleton et al. NEW ENGLAND JOURNAL OF MEDICINE
- ECFS best practice guidelines: the 2018 revision
- (2018) Carlo Castellani et al. Journal of Cystic Fibrosis
- The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial
- (2018) Katherine Ronchetti et al. Lancet Respiratory Medicine
- The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers
- (2017) Nicola J Rowbotham et al. THORAX
- Cystic fibrosis
- (2016) J Stuart Elborn LANCET
- Future trends in cystic fibrosis demography in 34 European countries
- (2015) Pierre-Régis Burgel et al. EUROPEAN RESPIRATORY JOURNAL
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies
- (2014) Ivan R. Diamond et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- European Cystic Fibrosis Society Standards of Care: Best Practice guidelines
- (2014) Alan R. Smyth et al. Journal of Cystic Fibrosis
- Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes
- (2013) Gregory S. Sawicki et al. Journal of Cystic Fibrosis
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More